Understanding how a protein called Galectin-3 affects blood vessel changes in pulmonary hypertension
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension
This work explores how a protein called Galectin-3 contributes to the harmful changes in lung blood vessels seen in pulmonary arterial hypertension, hoping to find new ways to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-11017021 on NIH RePORTER |
What this research studies
Pulmonary Arterial Hypertension (PAH) is a serious lung condition where blood vessels in the lungs become stiff and narrow, making it hard for blood to flow and leading to heart failure. Current treatments only manage symptoms and don't reverse these damaging changes. Our previous work showed that a protein called Galectin-3 plays a key role in this vessel remodeling, and blocking it helped prevent and even reverse PAH in animal models. This project aims to understand how Galectin-3 is controlled and how it causes these vessel changes, specifically looking at its connection to another protein called HIF2α. By understanding these mechanisms, we hope to develop new treatments that can truly reverse the disease.
Who could benefit from this research
Good fit: This foundational research is for patients with pulmonary arterial hypertension who are interested in the underlying causes of their condition and the development of future targeted therapies.
Not a fit: Patients seeking immediate new treatments or direct clinical trial participation may not find direct benefit from this basic science research at its current stage.
Why it matters
Potential benefit: If successful, this research could lead to new medications that not only treat the symptoms of pulmonary arterial hypertension but also reverse the damaging changes in lung blood vessels, potentially improving survival and quality of life for patients.
How similar studies have performed: Previous work by this team has shown promising results in animal models where blocking Galectin-3 prevented and reversed established PAH, suggesting this approach has potential.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Fulton, David J — Augusta University
- Study coordinator: Fulton, David J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.